Evidence map›Paper›PMID 39093975›Full record

ArticleScience advances2024

Dihydrothiazolo ring-fused 2-pyridone antimicrobial compounds treat

Zongsen Zou, Pardeep Singh, Jerome S Pinkner, Chloe L P Obernuefemann, Wei Xu, Taylor M Nye, Karen W Dodson, Fredrik Almqvist, Scott J Hultgren, Michael G Caparon

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Metabolic cross-talk promotes persistence ofbioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Pentamidine inhibition of streptopain attenuatesbioRxiv : the preprint server for biology · 2025
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zongsen ZouDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-4770-2144
Pardeep SinghDepartment of Chemistry, Umeå University, SE-90187 Umeå, Sweden.ORCID 0000-0003-1151-2936
Jerome S PinknerDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-7389-7440
Chloe L P ObernuefemannDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
Wei XuDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-4319-7432
Taylor M NyeDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-4695-0485
Karen W DodsonDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.
Fredrik AlmqvistDepartment of Chemistry, Umeå University, SE-90187 Umeå, Sweden.ORCID 0000-0002-0504-4446
Scott J HultgrenDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-8785-564X
Michael G CaparonDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-1171-0772

Funding

Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTIU19AI157797 · NIAID · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J. · 2021 to 2025
$11.4M
MOLECULAR BASIS OF E. COLI ADHESINS IN BLADDER DISORDERSR01DK051406 · NIDDK · WASHINGTON UNIVERSITY · PI SCOTT J. HULTGREN · 1997 to 2026
$8.8M
Chemical disarming of drug resistance in Mycobacterium tuberculosisR01AI134847 · NIAID · WASHINGTON UNIVERSITY · PI ALMQVIST, FREDRIK, STALLINGS, CHRISTINA LEIGH · 2018 to 2021
$2.7M
Novel Therapeutic Approach to Invasive Group A Streptococcal DiseaseR21AI163825 · NIAID · WASHINGTON UNIVERSITY · PI CAPARON, MICHAEL G. · 2022 to 2023
$432k
NIAID NIH HHS R01 AI134847NIAID NIH HHS R21 AI163825NIAID NIH HHS U19 AI157797NIDDK NIH HHS R01 DK051406
6 · The paper itself

Abstract

We have developed GmPcides from a peptidomimetic dihydrothiazolo ring-fused 2-pyridone scaffold that has antimicrobial activities against a broad spectrum of Gram-positive pathogens. Here, we examine the treatment efficacy of GmPcides using skin and soft tissue infection (SSTI) and biofilm formation models by

Indexed as

BiofilmsMicrobial Sensitivity TestsPyridonesSoft Tissue InfectionsStreptococcal InfectionsStreptococcus pyogenesAnimalsAnti-Bacterial AgentsDisease Models, AnimalFemaleHumansMiceSkin Diseases, BacterialThiazolesWound Healing2-hydroxypyridineAnti-Bacterial AgentsPyridonesThiazoles

Identifiers

PMID39093975
PMCPMC11296344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.